Over a month ago |
On The Fly
| ShowHide Related Items >><< - 11/29/22
- Wayfair reports five-day peak holiday comparable sales up low single digits
- 11/10/22
- Wayfair rises 32.9%
- 10/11/22
- Wayfair selects Google Cloud in shift to unified public cloud strategy
- 08/19/22
- Wayfair falls -17.4%
- 12/13/22
- Silvergate Capital falls -10.8%
- 12/05/22
- Silvergate Capital says all customers still have access to deposits
- 11/28/22
- Silvergate Capital says BlockFi deposit relationship limited to less than $20M
- 11/23/22
- block.one reports 7.46% passive stake in Silvergate Capital
- 12/21/22
- Mirati Therapeutics jumps 6% to $43.69 after adagrasib breakthrough designation
- 12/21/22
- Mirati Therapeutics gets FDA breakthrough therapy designation for adagrasib
- 12/12/22
- Mirati Therapeutics: FDA grants accelerated approval for KRAZATI
- 12/05/22
- Mirati Therapeutics announces results from KRYSTAL-7, KRYSTAL-1 trials
- 12/27/22
- Janux submits IND app for JANX008 to FDA for CRC, NSCLC and RCC treatment
- 10/12/22
- Janux Therapeutics doses first patient in JANX007 trial
- 11/23/22
- Film exhibitor stocks higher after report of Amazon spending plans
- 11/04/22
- Cinemark to open seven new theatres, 55 screens subsequent to 2022
- 10/06/22
- Netflix film 'Glass Onion' to have theatrical release before streaming debut
- 09/22/22
- Cinemark, D-BOX expand relationship with agreement for recliner seats
- 12/13/22 JPMorgan
- Silvergate Capital price target lowered to $30 from $50 at JPMorgan
- 12/12/22 Wedbush
- Silvergate Capital price target lowered to $30 from $45 at Wedbush
- 12/07/22 BTIG
- Signature Bank crypto news opens window of opportunity for Silvergate, says BTIG
- 12/05/22 Morgan Stanley
- Silvergate Capital downgraded to Underweight from Equal Weight at Morgan Stanley
- 12/14/22 Needham
- Mirati Therapeutics initiated with a Hold at Needham
- 12/14/22 Barclays
- Mirati Therapeutics price target lowered to $90 from $169 at Barclays
- 12/13/22 Piper Sandler
- Mirati Therapeutics price target lowered to $68 from $87 at Piper Sandler
- 12/13/22 Piper Sandler
- Mirati Therapeutics price target raised to $87 from $84 at Piper Sandler
- 12/15/22 Wolfe Research
- Wayfair initiated with a Peer Perform at Wolfe Research
- 12/13/22 Citi
- Wayfair initiated with a Buy at Citi
- 11/30/22 Stephens
- Wayfair five-day holiday sales report implies upside to consensus, says Stephens
- 11/21/22 Cowen
- Cowen downgrades Wayfair on home consumer demand concerns
- 12/21/22 Benchmark
- Cinemark price target lowered to $17 from $22 at Benchmark
- 11/07/22 B. Riley
- Cinemark price target lowered to $16 from $17 at B. Riley
- 10/27/22 Morgan Stanley
- Cinemark price target lowered to $16 from $22 at Morgan Stanley
- 10/12/22 B. Riley
- Cinemark price target lowered to $17 from $23 at B. Riley
- 03/02/22 Lake Street
- Big 5 Sporting price target lowered to $28 from $31 at Lake Street
- 01/28/22 Sidoti
- Big 5 Sporting initiated with a Buy at Sidoti
- 11/14/22 William Blair
- Janux Therapeutics initiated with an Outperform at William Blair
- 11/03/22
- Wayfair reports Q3 EPS ($2.11), consensus ($2.15)
- 11/02/22
- Notable companies reporting before tomorrow's open
- 08/04/22
- Wayfair sees Q3 revenue below Q2, consensus $3.11B
- 10/18/22
- Silvergate Capital reports Q3 EPS $1.28, consensus $1.38
- 07/19/22
- Silvergate Capital reports Q2 EPS $1.13, consensus 84c
- 07/18/22
- Notable companies reporting before tomorrow's open
- 11/08/22
- Mirati Therapeutics reports Q3 EPS ($3.09), consensus ($3.48)
- 08/03/22
- Mirati Therapeutics reports Q2 EPS ($3.18), consensus ($3.49)
- 11/10/22
- Janux Therapeutics reports Q3 EPS (40c), consensus (49c)
- 08/09/22
- Janux Therapeutics reports Q2 EPS (41c), consensus (37c)
- 11/04/22
- Cinemark reports Q3 EPS (20c), consensus (14c)
- 11/03/22
- Notable companies reporting before tomorrow's open
- 08/05/22
- Cinemark reports Q2 EPS (61c), consensus 23c
- 11/01/22
- Big 5 Sporting expects Q4 EPS 8c-20c, one est. 29c
- 11/01/22
- Big 5 Sporting reports Q3 EPS 29c vs. $1.07 last year
- 10/13/22
- E-commerce sites scale back ops amid online shopping shift, Bloomberg reports
- 12/06/22
- US Senators request information on Silvergate dealings with FTX, NBC reports
- 11/19/22
- Crypto's survival may now depend on Washington, Barron's says
- 11/09/22
- SEC expands probe into FTX, WSJ reports
- 11/09/22
- Binance to likely abandon FTX deal, WSJ reports
- 11/22/22
- Mirati Therapeutics seen as takeover target once again, Bloomberg reports
- 11/22/22
- Mirati Therapeutics drawing takeover interest, Bloomberg says
- 11/23/22
- Amazon to invest $1B a year in movies for theatrical release, Bloomberg says
- 08/15/22
- Summer movies show audiences, studio chiefs committed to theaters, WSJ reports
- 07/11/22
- U.S. box office sales rising closer to pre-pandemic levels, CNBC reports
- 12/30/22
- Sell these stocks now, proven algorithm says
- 12/15/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 12/13/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 12/09/22
- Sell these stocks now, proven algorithm says
- 12/16/22
- Here's What You Missed in Crypto This Week
- 12/09/22
- Here's What You Missed in Crypto This Week
- 12/05/22
- What You Missed On Wall Street On Monday
- 12/05/22
- What You Missed On Wall Street This Morning
- 12/16/22
- Sell these stocks now, proven algorithm says
- 12/12/22
- Fly Intel: After-Hours Movers
- 12/06/22
- What You Missed On Wall Street This Morning
- 12/06/22
- Fly Intel: Pre-market Movers
- 11/14/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 11/04/22
- Fly Intel: Pre-market Movers
- 10/12/22
- What You Missed On Wall Street On Wednesday
- 10/12/22
- What You Missed On Wall Street This Morning
- 10/12/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 11/01/22
- Fly Intel: After-Hours Movers
- 09/10/22
- Short Report: Asana shorts run for cover after strong earnings and CEO injection
- 12/22/22
- Wayfair put volume heavy and directionally bearish
- 11/14/22
- Wayfair put volume heavy and directionally bearish
- 11/04/22
- Wayfair put volume heavy and directionally bearish
- 10/18/22
- Wayfair call volume above normal and directionally bullish
- 12/21/22
- Largest borrow rate increases among liquid names
- 12/13/22
- Silvergate Capital Corp put volume heavy and directionally bearish
- 12/01/22
- Silvergate Capital Corp put volume heavy and directionally bearish
- 11/28/22
- Silvergate Capital Corp put volume heavy and directionally bearish
- 08/03/22
- new option listings and one option delisting on August 3rd
- 12/29/22
- Cinemark put volume heavy and directionally bearish
- 11/09/22
- Cinemark put volume heavy and directionally bearish
- 10/24/22
- Unusually active option classes on open October 24th
- 10/12/22
- Cinemark put volume heavy and directionally bearish
- 11/15/22
- Largest borrow rate increases among liquid names
- 09/06/22
- Largest borrow rate increases among liquid names
- 08/09/22
- Largest borrow rate increases among liquid names
- 08/04/22
- Largest borrow rate increases among liquid names
|
Hot Stocks
| ShowHide Related Items >><< - 12/21/22
- Mirati Therapeutics gets FDA breakthrough therapy designation for adagrasib
- 12/12/22
- Mirati Therapeutics: FDA grants accelerated approval for KRAZATI
- 12/05/22
- Mirati Therapeutics announces results from KRYSTAL-7, KRYSTAL-1 trials
- 12/14/22 Needham
- Mirati Therapeutics initiated with a Hold at Needham
- 12/14/22 Barclays
- Mirati Therapeutics price target lowered to $90 from $169 at Barclays
- 12/13/22 Piper Sandler
- Mirati Therapeutics price target lowered to $68 from $87 at Piper Sandler
- 12/13/22 Piper Sandler
- Mirati Therapeutics price target raised to $87 from $84 at Piper Sandler
- 11/08/22
- Mirati Therapeutics reports Q3 EPS ($3.09), consensus ($3.48)
- 08/03/22
- Mirati Therapeutics reports Q2 EPS ($3.18), consensus ($3.49)
- 11/22/22
- Mirati Therapeutics seen as takeover target once again, Bloomberg reports
- 11/22/22
- Mirati Therapeutics drawing takeover interest, Bloomberg says
- 12/16/22
- Sell these stocks now, proven algorithm says
- 12/12/22
- Fly Intel: After-Hours Movers
- 12/06/22
- What You Missed On Wall Street This Morning
- 12/06/22
- Fly Intel: Pre-market Movers
|
Hot Stocks
|
The company states:… The company states: "Mirati Therapeutics announced that the FDA has granted BTD to adagrasib in combination with cetuximab in patients with KRASG12C-mutated, advanced CRC whose cancer has progressed following prior treatment with chemotherapy and an anti-VEGF therapy. This designation is supported by results from the Phase 1b cohort of the KRYSTAL-1 trial. The FDA program grants BTD to expedite the development and regulatory review of drugs that have demonstrated preliminary clinical evidence of a substantial improvement over available therapy in the treatment of patients with serious diseases on at least one clinically significant endpoint. In addition, today, the NEJM published findings from the ongoing multicohort KRYSTAL-1 Phase 1/2 study evaluating adagrasib as monotherapy or combined with cetuximab in patients with KRASG12C-mutated metastatic colorectal cancer. These data reported promising clinical activity and demonstrated a favorable tolerability profile with reversible adverse events." ShowHide Related Items >><< - 12/12/22
- Mirati Therapeutics: FDA grants accelerated approval for KRAZATI
- 12/05/22
- Mirati Therapeutics announces results from KRYSTAL-7, KRYSTAL-1 trials
- 12/02/22
- Mirati Therapeutics provides update on Phase 3 SAPPHIRE study
- 12/14/22 Needham
- Mirati Therapeutics initiated with a Hold at Needham
- 12/14/22 Barclays
- Mirati Therapeutics price target lowered to $90 from $169 at Barclays
- 12/13/22 Piper Sandler
- Mirati Therapeutics price target lowered to $68 from $87 at Piper Sandler
- 12/13/22 Piper Sandler
- Mirati Therapeutics price target raised to $87 from $84 at Piper Sandler
- 11/08/22
- Mirati Therapeutics reports Q3 EPS ($3.09), consensus ($3.48)
- 08/03/22
- Mirati Therapeutics reports Q2 EPS ($3.18), consensus ($3.49)
- 11/22/22
- Mirati Therapeutics seen as takeover target once again, Bloomberg reports
- 11/22/22
- Mirati Therapeutics drawing takeover interest, Bloomberg says
- 12/16/22
- Sell these stocks now, proven algorithm says
- 12/12/22
- Fly Intel: After-Hours Movers
- 12/06/22
- What You Missed On Wall Street This Morning
- 12/06/22
- Fly Intel: Pre-market Movers
|
On The Fly
| ShowHide Related Items >><< - 11/02/22
- Xometry CEO sells $1.2M in common stock
- 10/05/22
- Xometry CEO sells $1.17M in common stock
- 10/03/22
- Xometry appoints Matt Leibel as CTO, Brendan Sterne as CPO
- 08/25/22
- Xometry, CCBC announce public-private partnership for two-year scholarships
- 12/13/22
- Cathie Wood's ARK Investment bought 49K shares of Verve Therapeutics today
- 12/12/22
- Cathie Wood's ARK Investment bought 58K shares of Verve Therapeutics today
- 12/07/22
- Cathie Wood's ARK Investment bought 106K shares of Verve Therapeutics today
- 12/06/22
- Cathie Wood's ARK Investment bought 330.4K shares of Verve Therapeutics today
- 11/22/22
- Toast director Bennett sells 132,709 class A shares
- 11/11/22
- Toast Inc trading resumes
- 11/11/22
- Toast Inc trading halted, volatility trading pause
- 11/10/22
- Toast jumps 8% to $21.60 after Q3 results and FY22 guidance raise
- 12/13/22
- Nogin names Bonham-Carter as Chief Revenue Officer
- 11/29/22
- Shopify reports Black Friday Cyber Monday weekend sales up 19% y/y
- 11/28/22
- Shopify rises 8.8%
- 11/28/22
- Shopify rises 8.3%
- 12/16/22
- Sea Limited falls -9.9%
- 11/15/22
- Sea Limited rises 36.9%
- 11/15/22
- Sea Limited rises 29.5%
- 11/15/22
- Sea Limited rises 24.2%
RXRX Recursion Pharmaceuticals - 09/13/22
- Recursion Pharmaceuticals initiates two additional clinical trials
- 07/21/22
- Recursion Pharmaceuticals granted EU orphan drug designation for REC-4881
- 06/20/22
- Recursion announces initiation of Phase 2/3 trial for NF2-Mutated Meningiomas
RADI Radius Global Infrastructure - 11/30/22
- Radius Global Infrastructure trading resumes
- 11/30/22
- Radius Global jumps 13%, halted after Bloomberg report on takeover talks
- 11/30/22
- Radius Global Infrastructure trading halted, volatility trading pause
- 11/08/22
- Radius Global Infrastructure backs FY22 Acquisition CapEx view at least $400M
- 12/14/22
- Paysafe falls -9.9%
- 12/14/22
- Paysafe falls -8.5%
- 12/08/22
- Paysafe announces reverse stock split
- 11/29/22
- Paysafe enters new partnership with Virgin Voyages
- 12/16/22
- Planet Labs rises 10.2%
- 12/16/22
- Satellite stocks take off after Maxar Technologies agrees to go private
- 12/14/22
- Planet Labs makes data available through Amazon Sagemaker
- 12/06/22
- Accenture announces sustainability collaboration with Planet Labs
- 12/12/22
- Mirati Therapeutics: FDA grants accelerated approval for KRAZATI
- 12/05/22
- Mirati Therapeutics announces results from KRYSTAL-7, KRYSTAL-1 trials
- 12/02/22
- Mirati Therapeutics provides update on Phase 3 SAPPHIRE study
- 11/22/22
- Mirati Therapeutics extends gain after volatility pause, now up 15%
- $51.49 /
+28.44 (+123.38%) - 12/16/22
- Maxar Technologies rises 122.5%
- 12/16/22
- Maxar Technologies rises 119.6%
- 12/16/22
- Maxar Technologies rises 120.5%
INM InMed Pharmaceuticals - 12/12/22
- InMed Pharmaceuticals engages Marcum LLP as auditor after KPMG resigns
- 12/12/22
- InMed Pharmaceuticals names Jonathan Tegge as interim CFO
- 11/18/22
- InMed Pharmaceuticals announces $6M private placement
- 11/17/22
- InMed Pharmaceuticals annouces Li promoted to VP of accounting, controller
- 12/06/22
- Freyr Battery, Nidec establish downstream joint venture
- 12/01/22
- Freyr Battery falls -12.7%
- 11/30/22
- Freyr Battery falls 13% to $11.92 after 13.5M share common stock offering
- 11/11/22
- Freyr Battery announces plan for Georgia Gigafactory
- 11/14/22
- Enviva names Thomas Meth CEO
- 11/02/22
- Enviva narrows FY22 adjusted EBITDA view to $240M-$260M from $230M-$270M
- 10/13/22
- ValueAct's Ubben bought 200,000 Enviva shares yesterday
- 10/12/22
- Enviva says shortseller report contains numerous errors
- 12/06/22
- Equinox Gold sells Solaris Resources shares for C$70.4M
- 10/19/22
- Equinox Gold announces results of Feasibility Study to expand Los Filos Mine
- 10/13/22
- Sandstorm Gold provides update on royalty portfolio
- 10/04/22
- Equinox Gold reports commercial production at Santa Luz Gold Mine
- 12/13/22
- Confluent appoints Shaun Clowes as chief product officer
- 12/09/22
- Carnival says delivery of Carnival Jubilee delayed
- 12/01/22
- Holland America Line reports 'record' Black Friday bookings in the U.S.
- 11/29/22
- Carnival says Cyber Monday bookings 50% above volume for Cyber Monday 2019
- 11/15/22
- Carnival falls 11% to $9.95 after $1B convertible senior notes offering
INM InMed Pharmaceuticals - 05/16/22 Roth MKM
- InMed Pharmaceuticals downgraded to Neutral from Buy at Roth Capital
- 12/14/22 Needham
- Mirati Therapeutics initiated with a Hold at Needham
- 12/14/22 Barclays
- Mirati Therapeutics price target lowered to $90 from $169 at Barclays
- 12/13/22 Piper Sandler
- Mirati Therapeutics price target lowered to $68 from $87 at Piper Sandler
- 12/13/22 Piper Sandler
- Mirati Therapeutics price target raised to $87 from $84 at Piper Sandler
- 11/21/22 Cowen
- Sea Limited downgraded on lack of visibility at Cowen
- 11/21/22 Cowen
- Sea Limited downgraded to Market Perform from Outperform at Cowen
- 11/17/22 Morgan Stanley
- Sea Limited price target lowered to $95 from $116 at Morgan Stanley
- 11/16/22 Cowen
- Sea Limited price target lowered to $72 from $78 at Cowen
- 12/16/22 Wells Fargo
- Wells Fargo sees significant opportunity ahead for Toast
- 12/12/22 Mizuho
- Fiserv price target lowered to $135 from $145 at Mizuho
- 11/29/22 Wolfe Research
- Toast initiated with a Peer Perform at Wolfe Research
- 11/11/22 Needham
- Toast price target raised to $32 from $27 at Needham
- 12/09/22 SMBC Nikko
- Shopify price target raised to $45 from $40 at SMBC Nikko
- 12/08/22 Capital One
- Shopify initiated with an Equalweight at Capital One
- 12/08/22 UBS
- Shopify initiated with a Sell at UBS
- 12/08/22 Mizuho
- Shopify price target raised to $40 from $33 at Mizuho
- 12/07/22 National Bank
- Equinox Gold price target raised to C$5.50 from C$5 at National Bank
- 12/07/22 BMO Capital
- Equinox Gold price target raised to C$6.50 from C$6 at BMO Capital
- 11/07/22 BMO Capital
- Equinox Gold price target lowered to C$6 from C$7.50 at BMO Capital
- 11/04/22 National Bank
- Equinox Gold price target lowered to C$4 from C$5 at National Bank
- 11/03/22 DA Davidson
- Confluent price target lowered to $33 from $44 at DA Davidson
- 11/03/22 Credit Suisse
- Confluent price target lowered to $55 from $65 at Credit Suisse
- 11/03/22 Barclays
- Confluent price target lowered to $27 from $30 at Barclays
- 11/01/22 Citi
- Confluent price target lowered to $30 from $32 at Citi
- 12/14/22 Lake Street
- Xometry initiated with a Sell at Lake Street
- 12/13/22 Citi
- Xometry initiated with a Buy at Citi
- 11/11/22 UBS
- Xometry price target lowered to $45 from $55 at UBS
- 08/24/22 JPMorgan
- JPMorgan cuts Xometry target but still sees 46% upside potential
RADI Radius Global Infrastructure - 12/16/22 RBC Capital
- Radius Global Infrastructure initiated with a Sector Perform at RBC Capital
- 12/14/22 Exane BNP Paribas
- Radius Global Infrastructure initiated with an Outperform at Exane BNP Paribas
- 10/04/22 Raymond James
- Radius Global Infrastructure price target lowered to $17 from $21 at Raymond James
- 05/10/22 Raymond James
- Radius Global Infrastructure price target raised to $22 from $18 at Raymond James
- 11/08/22 Deutsche Bank
- Planet Labs initiated with a Buy at Deutsche Bank
- 09/13/22 Needham
- Planet Labs price target raised to $9 from $8 at Needham
- 06/15/22 Craig-Hallum
- Planet Labs price target lowered to $10 from $15 at Craig-Hallum
- 06/15/22 Needham
- Planet Labs price target lowered to $8.00 from $10.50 at Needham
- 08/31/22 Susquehanna
- Susquehanna downgrades Paysafe after CFO change, prefers to 'wait and see'
- 08/31/22 Susquehanna
- Paysafe downgraded to Neutral from Positive at Susquehanna
- 08/11/22 Credit Suisse
- Paysafe downgraded to Underperform from Neutral at Credit Suisse
- 08/10/22 RBC Capital
- Paysafe downgraded to Sector Perform from Outperform at RBC Capital
- 10/31/22 Cowen
- Cowen starts Freyr Battery at Outperform, sees 'less technology risk'
- 10/31/22 Cowen
- Freyr Battery initiated with an Outperform at Cowen
- 09/21/22 Morgan Stanley
- Freyr Battery price target raised to $26, named a 'Top Pick' at Morgan Stanley
- 09/01/22 BTIG
- Freyr Battery price target raised to $25 from $20 at BTIG
- 12/15/22 Goldman Sachs
- Verve Therapeutics initiated with a Sell at Goldman Sachs
- 12/05/22 Stifel
- Verve FDA request 'provides fodder for both bulls and bears,' says Stifel
- 12/02/22 Guggenheim
- Beam hold being lifted 'encouraging' for Verve Therapeutics, says Guggenheim
- 10/06/22 Credit Suisse
- Verve Therapeutics initiated with a Neutral at Credit Suisse
- 12/15/22 Barclays
- Carnival price target raised to $12 from $10 at Barclays
- 12/14/22 Stifel
- Carnival price target raised to $18 at Stifel, would buy ahead of Q4 report
- 12/12/22 Credit Suisse
- Credit Suisse keeps Outperform on Carnival, lowers price target to $19
- 12/06/22 JPMorgan
- Carnival assumed with a Neutral at JPMorgan
- 11/29/22 RBC Capital
- Enviva price target lowered to $63 from $76 at RBC Capital
- 10/20/22 JPMorgan
- Enviva price target lowered to $60 from $66 at JPMorgan
- 10/18/22 Raymond James
- Enviva upgraded to Strong Buy from Outperform at Raymond James
- 10/14/22 Citi
- Citi upgrades Enviva to Buy, says short report selloff overdone
RXRX Recursion Pharmaceuticals - 09/15/22 KeyBanc
- Recursion Pharmaceuticals initiated with an Overweight at KeyBanc
- 04/18/22 BofA
- Recursion Pharmaceuticals downgraded to Neutral from Buy at BofA
- 03/04/22 SVB Securities
- Recursion Pharmaceuticals downgraded to Market Perform from Outperform at SVB Leerink
- $51.49 /
+28.44 (+123.38%) - 12/16/22 Wells Fargo
- Maxar Technologies downgraded to Equal Weight from Overweight at Wells Fargo
- 12/16/22 Canaccord
- Maxar Technologies downgraded to Hold from Buy at Canaccord
- 12/16/22 Truist
- Maxar Technologies downgraded to Hold from Buy at Truist
- 11/23/22 Truist
- Maxar Technologies price target lowered to $37 from $44 at Truist
- 11/10/22
- Xometry sees Q4 revenue $104M-$106M, consensus $116.11M
- 11/10/22
- Xometry reports Q3 adjusted EPS (11c), consensus (22c)
- 08/10/22
- Xometry sees 2022 revenue $395M-$400M, consensus $397.09M
- 08/10/22
- Xometry sees Q3 revenue $102M-$104M, consensus $103.9M
- 11/07/22
- Verve Therapeutics reports Q3 EPS (79c), consensus (74c)
- 08/09/22
- Verve Therapeutics reports Q2 EPS (84c), consensus (63c)
- 11/10/22
- Toast raises FY22 revenue view to $2.692B-$2.722B from $2.62B-$2.66B
- 11/10/22
- Toast sees Q4 revenue $730M-$760M, consensus $731.31M
- 11/10/22
- Toast reports Q3 EPS (19c), consensus (9c)
- 08/11/22
- Toast raises FY22 revenue view to $2.62B-$2.66B, consensus $2.54B
- 10/27/22
- Shopify reports Q3 adjusted EPS (2c), consensus (10c)
- 10/26/22
- Notable companies reporting before tomorrow's open
- 07/27/22
- Shopify reports Q2 adjusted EPS (3c), consensus 3c
- 11/15/22
- Sea Limited reports Q3 EPS (66c), consensus ($1.09)
- 08/16/22
- Sea Limited suspends FY22 e-commerce GAAP guidance
- 08/16/22
- Sea Limited reports Q2 EPS ($1.03), consensus ($1.19)
RXRX Recursion Pharmaceuticals - 11/08/22
- Recursion Pharmaceuticals reports Q3 EPS (35c), consensus (38c)
- 08/09/22
- Recursion Pharmaceuticals reports Q2 EPS (38c), consensus (35c)
RADI Radius Global Infrastructure - 11/08/22
- Radius Global Infrastructure reports Q3 EPS 23c, consensus (26c)
- 11/10/22
- Paysafe sees Q4 revenue $370M-$378M, consensus $370.81M
- 11/10/22
- Paysafe raises FY22 revenue view to $1.48B-$1.49B from $1.47B-$1.49B
- 11/10/22
- Paysafe reports Q3 EPS 0c, consensus 0c
- 12/14/22
- Planet Labs raises FY23 revenue view to $188M-$192M from $182M-$190M
- 12/14/22
- Planet Labs sees Q4 revenue $50M-$54M, consensus $51.2M
- 12/14/22
- Planet Labs reports Q3 EPS (15c), consensus (17c)
- 09/12/22
- Planet Labs sees FY23 revenue $182M-$190M, consensus $182.03M
- 11/08/22
- Mirati Therapeutics reports Q3 EPS ($3.09), consensus ($3.48)
- 08/03/22
- Mirati Therapeutics reports Q2 EPS ($3.18), consensus ($3.49)
- $51.49 /
+28.44 (+123.38%) - 11/03/22
- Maxar Technologies reports Q3 EPS (5c), consensus 29c
- 08/09/22
- Maxar Technologies reports Q2 EPS (41c) vs 62c last year
INM InMed Pharmaceuticals - 11/11/22
- InMed Pharmaceuticals reports Q1 EPS ($4.06) vs. ($6.17) a year ago
- 09/23/22
- InMed Pharmaceuticals reports FY22 EPS ($33.17) vs. ($37.96) last year
- 11/14/22
- Freyr Battery reports Q3 EPS (80c), consensus (30c)
- 08/08/22
- Freyr Battery reports Q2 EPS 4c, consensus (26c)
- 11/02/22
- Enviva reports Q3 revenue $325.7M, consensus $352.16M
- 08/03/22
- Enviva backs FY22 adjusted EBITDA $230M-$270M
- 08/03/22
- Enviva reports Q2 revenue $296.3M, consensus $286.26M
- 06/21/22
- Enviva backs FY22 adjusted EBITDA view $230M-$270M
- 08/03/22
- Equinox Gold reports Q2 EPS (26c) vs. $1.19 last year
- 11/02/22
- Confluent raises FY22 EPS view to (65c)-(63c) from (73c)-(69c), consensus (70c)
- 11/02/22
- Confluent sees Q4 adjusted EPS (16c)-(14c), consensus (17c)
- 11/02/22
- Confluent reports Q3 adjusted EPS (13c), consensus (17c)
- 08/03/22
- Confluent raises FY22 EPS view to (73c)-(69c) from (79c)-(73c), consensus (75c)
- 09/30/22
- Carnival sees net loss, breakeven to slightly negative adjusted EBITDA in Q4
- 09/30/22
- Carnival reports Q3 EPS (65c), consensus (13c)
- 09/29/22
- Notable companies reporting before tomorrow's open
|
Initiation
|
Needham analyst Ami Fadia… Needham analyst Ami Fadia initiated coverage of Mirati Therapeutics with a Hold rating and no price target. Despite the recent pullback, Fadia struggles to see a path to near-term upside, the analyst tells investors in a research note. Last week's ESMO update puts into question adagrasib's likelihood of success in 1L NSCLC, particularly in TPS greater than or equal to 1%, the analyst adds. ShowHide Related Items >><< - 12/12/22
- Mirati Therapeutics: FDA grants accelerated approval for KRAZATI
- 12/05/22
- Mirati Therapeutics announces results from KRYSTAL-7, KRYSTAL-1 trials
- 12/02/22
- Mirati Therapeutics provides update on Phase 3 SAPPHIRE study
- 11/22/22
- Mirati Therapeutics extends gain after volatility pause, now up 15%
- 12/14/22 Barclays
- Mirati Therapeutics price target lowered to $90 from $169 at Barclays
- 12/13/22 Piper Sandler
- Mirati Therapeutics price target lowered to $68 from $87 at Piper Sandler
- 12/13/22 Piper Sandler
- Mirati Therapeutics price target raised to $87 from $84 at Piper Sandler
- 11/08/22
- Mirati Therapeutics reports Q3 EPS ($3.09), consensus ($3.48)
- 08/03/22
- Mirati Therapeutics reports Q2 EPS ($3.18), consensus ($3.49)
- 11/22/22
- Mirati Therapeutics seen as takeover target once again, Bloomberg reports
- 11/22/22
- Mirati Therapeutics drawing takeover interest, Bloomberg says
- 12/12/22
- Fly Intel: After-Hours Movers
- 12/06/22
- What You Missed On Wall Street This Morning
- 12/06/22
- Fly Intel: Pre-market Movers
- 11/25/22
- Biotech Alert: Searches spiking for these stocks today
|
Recommendations
|
Barclays analyst Gena… Barclays analyst Gena Wang lowered the firm's price target on Mirati Therapeutics to $90 from $169 and keeps an Overweight rating on the shares. The company received Krazati accelerated approval and the label is largely consistent with Amgen's Lumakras, Wang tells investors in a research note. The analyst expects a gradual uptake given its second to market status, and believes a differentiated profile could lead to greater market share in the longer-term. She dropped the price target to reflect Mirati's recent updates. ShowHide Related Items >><< - 12/12/22
- Mirati Therapeutics: FDA grants accelerated approval for KRAZATI
- 12/05/22
- Mirati Therapeutics announces results from KRYSTAL-7, KRYSTAL-1 trials
- 12/02/22
- Mirati Therapeutics provides update on Phase 3 SAPPHIRE study
- 11/22/22
- Mirati Therapeutics extends gain after volatility pause, now up 15%
- 12/13/22 Piper Sandler
- Mirati Therapeutics price target lowered to $68 from $87 at Piper Sandler
- 12/13/22 Piper Sandler
- Mirati Therapeutics price target raised to $87 from $84 at Piper Sandler
- 12/09/22 Stifel
- Stifel cuts Mirati price target to $73, says move lower 'overdone'
- 12/09/22 Citi
- Mirati Therapeutics downgraded to Neutral from Buy at Citi (yesterday)
- 11/08/22
- Mirati Therapeutics reports Q3 EPS ($3.09), consensus ($3.48)
- 08/03/22
- Mirati Therapeutics reports Q2 EPS ($3.18), consensus ($3.49)
- 11/22/22
- Mirati Therapeutics seen as takeover target once again, Bloomberg reports
- 11/22/22
- Mirati Therapeutics drawing takeover interest, Bloomberg says
- 12/12/22
- Fly Intel: After-Hours Movers
- 12/06/22
- What You Missed On Wall Street This Morning
- 12/06/22
- Fly Intel: Pre-market Movers
- 11/25/22
- Biotech Alert: Searches spiking for these stocks today
|
Recommendations
|
Piper Sandler analyst… Piper Sandler analyst Swapnil Malekar lowered the firm's price target on Mirati Therapeutics to $68 from $87 but keeps an Overweight rating on the shares. Mirati Therapeutics priced Krazati at a slight premium vs Lumakras and justified the overage based on advantage seen in CNSmet patients and a better safety profile, but he remains cautious until this theory pans out in the real world given the brain-met language or the safety data from tablet formulation was not reflected in the label, the analyst tells investors in a research note. ShowHide Related Items >><< - 12/12/22
- Mirati Therapeutics: FDA grants accelerated approval for KRAZATI
- 12/05/22
- Mirati Therapeutics announces results from KRYSTAL-7, KRYSTAL-1 trials
- 12/02/22
- Mirati Therapeutics provides update on Phase 3 SAPPHIRE study
- 11/22/22
- Mirati Therapeutics extends gain after volatility pause, now up 15%
- 12/13/22 Piper Sandler
- Mirati Therapeutics price target raised to $87 from $84 at Piper Sandler
- 12/09/22 Stifel
- Stifel cuts Mirati price target to $73, says move lower 'overdone'
- 12/09/22 Citi
- Mirati Therapeutics downgraded to Neutral from Buy at Citi (yesterday)
- 12/08/22 BofA
- Mirati Therapeutics price target lowered to $61 from $100 at BofA
- 11/08/22
- Mirati Therapeutics reports Q3 EPS ($3.09), consensus ($3.48)
- 08/03/22
- Mirati Therapeutics reports Q2 EPS ($3.18), consensus ($3.49)
- 11/22/22
- Mirati Therapeutics seen as takeover target once again, Bloomberg reports
- 11/22/22
- Mirati Therapeutics drawing takeover interest, Bloomberg says
- 12/12/22
- Fly Intel: After-Hours Movers
- 12/06/22
- What You Missed On Wall Street This Morning
- 12/06/22
- Fly Intel: Pre-market Movers
- 11/25/22
- Biotech Alert: Searches spiking for these stocks today
|
Recommendations
|
Piper Sandler analyst… Piper Sandler analyst Swapnil Malekar raised the firm's price target on Mirati Therapeutics to $87 from $84 and keeps an Overweight rating on the shares. The company received FDA approval for Krazati with the label language in line with the efficacy seen in the K-1 study, Malekar tells investors in a research note. The analyst views the overall label language to be largely similar to Lumakras and believes that the risk/benefit profile of the two drugs is identical. ShowHide Related Items >><< - 12/12/22
- Mirati Therapeutics: FDA grants accelerated approval for KRAZATI
- 12/05/22
- Mirati Therapeutics announces results from KRYSTAL-7, KRYSTAL-1 trials
- 12/02/22
- Mirati Therapeutics provides update on Phase 3 SAPPHIRE study
- 11/22/22
- Mirati Therapeutics extends gain after volatility pause, now up 15%
- 12/09/22 Stifel
- Stifel cuts Mirati price target to $73, says move lower 'overdone'
- 12/09/22 Citi
- Mirati Therapeutics downgraded to Neutral from Buy at Citi (yesterday)
- 12/08/22 BofA
- Mirati Therapeutics price target lowered to $61 from $100 at BofA
- 12/08/22 JPMorgan
- Mirati Therapeutics downgraded to Neutral from Overweight at JPMorgan
- 11/08/22
- Mirati Therapeutics reports Q3 EPS ($3.09), consensus ($3.48)
- 08/03/22
- Mirati Therapeutics reports Q2 EPS ($3.18), consensus ($3.49)
- 11/22/22
- Mirati Therapeutics seen as takeover target once again, Bloomberg reports
- 11/22/22
- Mirati Therapeutics drawing takeover interest, Bloomberg says
- 12/12/22
- Fly Intel: After-Hours Movers
- 12/06/22
- What You Missed On Wall Street This Morning
- 12/06/22
- Fly Intel: Pre-market Movers
- 11/25/22
- Biotech Alert: Searches spiking for these stocks today
|